Overview
Osteoporosis (OP) is a skeletal disorder characterized by reduced bone mass and deterioration of bone tissue microarchitecture, leading to increased bone fragility and susceptibility to fractures 1. This condition significantly impacts quality of life and imposes a substantial financial burden on healthcare systems due to the high costs associated with fracture-related complications 45. Osteoporosis predominantly affects postmenopausal women and older adults, with a notable prevalence among individuals with hypertension, particularly in aging populations such as China 89. Accurate risk assessment and early intervention are crucial in day-to-day practice to mitigate fracture risks and improve patient outcomes 1.Pathophysiology
Osteoporosis develops through complex interactions at the molecular, cellular, and organ levels. At the cellular level, the balance between bone formation by osteoblasts and bone resorption by osteoclasts is disrupted, often tipped towards excessive resorption 1. Hormonal changes, particularly decreases in estrogen and testosterone, play pivotal roles in accelerating bone loss 1. Additionally, inflammation and oxidative stress contribute to the pathogenesis by promoting osteoclast activity and impairing osteoblast function 1. The interplay between systemic factors like hypertension and metabolic alterations, such as visceral adiposity, further complicates bone metabolism. For instance, while visceral adipose tissue (VAT) has been implicated in both detrimental and protective effects on bone health (the "obesity paradox"), the underlying mechanisms remain incompletely understood 1115. Recent evidence suggests that specific antihypertensive drugs may influence bone metabolism differently, with angiotensin receptor blockers (ARBs) potentially enhancing bone density by stimulating osteoblast activity and reducing osteoclast generation 2.Epidemiology
Osteoporosis exhibits significant variability in incidence and prevalence based on demographic factors. Globally, the prevalence of osteoporosis increases with age, particularly among postmenopausal women, with estimates suggesting a 1 in 3 women and 1 in 5 men over 50 years will experience an osteoporotic fracture 1. In China, the prevalence of osteoporosis is notably higher among elderly hypertensive patients compared to normotensive individuals, reflecting the compounded risk associated with aging and comorbid conditions 89. Geographic variations also exist, with certain ethnic groups showing higher susceptibility due to genetic predispositions and lifestyle factors 24. Trends indicate a rising prevalence due to aging populations and increased life expectancy, underscoring the growing public health concern 8.Clinical Presentation
Clinical manifestations of osteoporosis are often silent until a fragility fracture occurs, typically in the hip, spine, or wrist 1. Common presenting features include back pain, loss of height, and stooped posture (kyphosis), which can signal vertebral fractures 1. Red-flag symptoms such as sudden severe back pain, acute collapse, or noticeable deformity should prompt urgent evaluation for fractures 1. Early detection through screening and risk assessment tools is crucial to prevent these complications and guide timely intervention 1.Diagnosis
The diagnostic approach to osteoporosis involves a combination of clinical risk assessment and bone mineral density (BMD) measurement. Clinicians should evaluate risk factors including age, sex, family history, lifestyle factors, and comorbidities such as hypertension 1. Specific diagnostic criteria include:Bone Mineral Density (BMD) Testing: Dual-energy X-ray absorptiometry (DXA) is the gold standard, with osteoporosis defined by a T-score ≤ -2.5 at the femoral neck, total hip, or lumbar spine 12.
FRAX Score: The Fracture Risk Assessment Tool (FRAX) incorporates clinical risk factors to estimate the 10-year probability of hip fracture and major osteoporotic fracture 1.
Visceral Adiposity Index (CVAI): In Chinese populations, the Chinese Visceral Adiposity Index (CVAI) can provide additional insights into bone health, correlating with BMD and fracture risk 1. Elevated CVAI values may indicate a higher risk profile 1.Differential Diagnosis:
Osteomalacia/Rickets: Characterized by bone deformities and muscle weakness, often with elevated alkaline phosphatase levels 1.
Paget’s Disease: Presents with bone pain, deformities, and elevated markers of bone turnover 1.
Secondary Osteoporosis: Caused by underlying conditions like hyperthyroidism, chronic kidney disease, or malabsorption syndromes, requiring specific management of the underlying cause 1.Management
First-Line Management
Lifestyle Modifications:
- Calcium and Vitamin D Supplementation: Calcium 1000-1200 mg/day and Vitamin D 800-1000 IU/day to support bone health 1.
- Weight-Bearing Exercise: Regular physical activity, such as walking, resistance training, to enhance bone density 1.
- Fall Prevention: Environmental modifications and balance exercises to reduce fall risk 1.Pharmacotherapy:
- Bisphosphonates: Alendronate 70 mg weekly, Risedronate 35 mg monthly, or Ibandronate 150 mg every 3 months 1.
- Selective Estrogen Receptor Modulators (SERMs): Raloxifene 60 mg daily for postmenopausal women 1.Second-Line Management
Advanced Pharmacotherapy:
- Denosumab: Subcutaneous injection every 6 months 1.
- Teriparatide: Daily injection of parathyroid hormone analog, 20 mcg, for up to 2 years 1.
- Romosozumab: Monthly intravenous injections for severe osteoporosis, typically used after failure of prior treatments 1.Refractory Cases / Specialist Referral
Comprehensive Evaluation: Including endocrinology consultation for secondary causes and metabolic bone disease specialists 1.
Multidisciplinary Approach: Involving orthopedics for fracture management and geriatrics for comprehensive care 1.Contraindications:
Bisphosphonates: Renal impairment, hypocalcemia, and known hypersensitivity 1.
Teriparatide: Paget’s disease, hyperparathyroidism, and uncorrected hypocalcemia 1.Complications
Fractures: Hip, vertebral, and wrist fractures are common, often leading to significant morbidity and reduced mobility 1.
Chronic Pain: Persistent back pain and disability post-fracture 1.
Compression Fractures: Leading to kyphosis and decreased lung function 1.
Referral Triggers: Persistent pain, multiple fractures, or inadequate response to initial treatment warrant specialist referral 1.Prognosis & Follow-Up
The prognosis of osteoporosis varies widely depending on the severity of bone loss and adherence to treatment. Prognostic indicators include baseline BMD, age, and presence of multiple risk factors 1. Recommended follow-up intervals typically include:
Annual BMD Monitoring: To assess treatment efficacy 1.
Biannual Clinical Reviews: To evaluate adherence, side effects, and adjust therapy as needed 1.
Periodic FRAX Recalculation: Every 2-3 years to reassess fracture risk 1.Special Populations
Elderly: Higher prevalence and increased fracture risk necessitate more frequent monitoring and aggressive management 89.
Hypertension: Specific antihypertensive drugs like ARBs may offer protective effects on bone health 23.
Chinese Population: CVAI can be a valuable tool for assessing visceral adiposity and its impact on bone health 1.
Comorbidities: Conditions like hyperthyroidism or chronic kidney disease require tailored management strategies addressing both osteoporosis and underlying diseases 1.Key Recommendations
Screen High-Risk Individuals: Use FRAX tool and BMD testing for postmenopausal women and men over 50 with risk factors (Evidence: Strong 1).
Lifestyle Interventions: Recommend calcium and vitamin D supplementation, weight-bearing exercises, and fall prevention strategies (Evidence: Strong 1).
Initiate Pharmacotherapy: Start with bisphosphonates for primary prevention and treatment of osteoporosis (Evidence: Strong 1).
Consider CVAI in Chinese Populations: Incorporate CVAI for assessing visceral adiposity and its impact on bone health (Evidence: Moderate 1).
Monitor Treatment Efficacy: Perform annual BMD assessments and clinical reviews every 6-12 months (Evidence: Moderate 1).
Special Attention to Hypertension: Evaluate the potential benefits of ARBs in patients with hypertension (Evidence: Moderate 23).
Refer Complex Cases: Escalate to specialists for refractory cases or those with multiple comorbidities (Evidence: Expert opinion 1).
Manage Secondary Causes: Investigate and treat underlying conditions contributing to secondary osteoporosis (Evidence: Moderate 1).
Educate Patients: Emphasize the importance of adherence to treatment and lifestyle modifications (Evidence: Expert opinion 1).
Regular Follow-Up: Schedule periodic reassessment of fracture risk and treatment efficacy (Evidence: Moderate 1).References
1 Ma R, Cai X, Song S, Ma H, Hu J, Shen D et al.. Association of CVAI with BMD, FRAX scores, and osteoporosis risk in Chinese elderly patients with hypertension. Scientific reports 2025. link
2 Zhang R, Yin H, Yang M, Lei X, Zhen D, Zhang Z. Advanced Progress of the Relationship Between Antihypertensive Drugs and Bone Metabolism. Hypertension (Dallas, Tex. : 1979) 2023. link
3 Wu J, Wang M, Guo M, Du XY, Tan XZ, Teng FY et al.. Angiotensin Receptor Blocker is Associated with a Lower Fracture Risk: An Updated Systematic Review and Meta-Analysis. International journal of clinical practice 2022. link